| Primary Action | Dual hormone system targeting satiety + glucose regulation | Triple receptor activation (GLP-1, GIP, Glucagon) | Dual receptor activation (GLP-1 + GIP) | Single GLP-1 receptor activation |
| Mechanism | Suppresses appetite and cravings while improving insulin control | Enhances energy expenditure, fat oxidation, and insulin response | Increases insulin sensitivity and reduces appetite | Slows gastric emptying and reduces hunger signals |
| Key Benefits | Rapid appetite suppression, enhanced fullness, steady fat loss | Strongest fat-loss potential, improved lean mass retention | Sustained weight loss, better insulin regulation, metabolic stability | Gradual fat loss, steady appetite control, cardiometabolic support |
| Energy / Focus Effect | Moderate, smooth focus from stable glucose | High – boosts both metabolic and energy output | Moderate – promotes steady energy balance | Mild – smoother energy curve |
| Lean Muscle Preservation | ✔️ | ✔️✔️ | ✔️ | ⚪ (maintains muscle if paired with protein intake) |
| Typical Weekly Dose | 0.25 mg → 2.4 mg (Semaglutide component) | 5 mg → 12 mg | 2.5 mg → 12.5 mg | 0.25 mg → 2.4 mg |
| Half-Life | ~165 h (≈ 7 days) | ~120 h (≈ 5 days) | ~120 h (≈ 5 days) | ~165 h (≈ 7 days) |
| Onset of Effect | Fast (within 1–2 weeks) | Very Fast (1 week) | Moderate (2–3 weeks) | Gradual (3–4 weeks) |
| Best For | Appetite suppression & smoother fat loss | Maximum metabolic acceleration & advanced users | Balanced fat loss & insulin control | Beginners or long-term weight management |
| Formulation | Dual peptide (Cagrilintide + Semaglutide) | Single peptide (Triple Agonist) | Single peptide (Dual Agonist) | Single peptide (GLP-1 only) |
| Recommended Use | Intermediate to advanced | Advanced users | Intermediate | Entry-level / maintenance |
| Storage | 2–8 °C (refrigerated) | 2–8 °C (refrigerated) | 2–8 °C (refrigerated) | 2–8 °C (refrigerated) |
